Tecan Group AG

BATS-CHIXE:TECNZ Stock Report

Market Cap: CHF 1.8b

Tecan Group Valuation

Is TECNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TECNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 232.04
Fair Value
40.4% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: TECNZ (CHF138.3) is trading below our estimate of fair value (CHF232.04)

Significantly Below Fair Value: TECNZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TECNZ?

Key metric: As TECNZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TECNZ. This is calculated by dividing TECNZ's market cap by their current earnings.
What is TECNZ's PE Ratio?
PE Ratio27.8x
EarningsCHF 63.13m
Market CapCHF 1.76b

Price to Earnings Ratio vs Peers

How does TECNZ's PE Ratio compare to its peers?

The above table shows the PE ratio for TECNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29x
HVO hVIVO
7.3x21.30%UK£38.5m
GNS Genus
91.2x23.17%UK£1.8b
HCM HUTCHMED (China)
5.4x-64.67%UK£1.9b
HIK Hikma Pharmaceuticals
12.3x13.17%UK£3.4b
TECNZ Tecan Group
27.8x15.99%CHF 1.8b

Price-To-Earnings vs Peers: TECNZ is good value based on its Price-To-Earnings Ratio (27.8x) compared to the peer average (29x).

Price to Earnings Ratio vs Industry

How does TECNZ's PE Ratio compare vs other companies in the European Life Sciences Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies3PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TECNZ is good value based on its Price-To-Earnings Ratio (27.8x) compared to the Global Life Sciences industry average (36x).

Price to Earnings Ratio vs Fair Ratio

What is TECNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TECNZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.8x
Fair PE Ratio18x

Price-To-Earnings vs Fair Ratio: TECNZ is expensive based on its Price-To-Earnings Ratio (27.8x) compared to the estimated Fair Price-To-Earnings Ratio (18x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TECNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 138.30
CHF 202.48
+46.40%
34.77%CHF 384.00CHF 158.00n/a8
Nov ’26CHF 146.20
CHF 205.98
+40.89%
33.32%CHF 384.00CHF 160.00n/a8
Oct ’26CHF 149.80
CHF 220.64
+47.29%
29.58%CHF 384.00CHF 166.80n/a9
Sep ’26CHF 164.50
CHF 220.47
+34.02%
29.67%CHF 384.00CHF 165.20n/a9
Aug ’26CHF 161.80
CHF 225.02
+39.07%
28.05%CHF 384.00CHF 165.20n/a9
Jul ’26CHF 161.40
CHF 227.13
+40.73%
27.44%CHF 384.00CHF 165.20n/a9
Jun ’26CHF 164.60
CHF 239.29
+45.37%
26.74%CHF 384.00CHF 188.00n/a7
May ’26CHF 159.00
CHF 250.29
+57.41%
23.31%CHF 384.00CHF 192.00n/a7
Apr ’26CHF 163.70
CHF 250.29
+52.89%
23.31%CHF 384.00CHF 192.00n/a7
Mar ’26CHF 195.10
CHF 271.67
+39.24%
20.13%CHF 384.00CHF 225.00n/a6
Feb ’26CHF 236.00
CHF 283.83
+20.27%
17.95%CHF 384.00CHF 230.00n/a6
Jan ’26CHF 201.40
CHF 284.86
+41.44%
15.61%CHF 384.00CHF 241.00n/a7
Dec ’25CHF 210.00
CHF 286.14
+36.26%
15.64%CHF 384.00CHF 241.00n/a7
Nov ’25CHF 220.80
CHF 295.29
+33.73%
15.52%CHF 384.00CHF 241.00CHF 146.207
Oct ’25CHF 275.60
CHF 348.75
+26.54%
10.99%CHF 415.00CHF 300.00CHF 149.808
Sep ’25CHF 285.20
CHF 351.71
+23.32%
11.41%CHF 415.00CHF 300.00CHF 164.507
Aug ’25CHF 326.80
CHF 385.71
+18.03%
8.23%CHF 415.00CHF 330.00CHF 161.807
Jul ’25CHF 300.40
CHF 396.57
+32.01%
5.78%CHF 418.00CHF 347.00CHF 161.407
Jun ’25CHF 320.90
CHF 397.71
+23.94%
5.99%CHF 420.00CHF 347.00CHF 164.607
May ’25CHF 330.20
CHF 395.57
+19.80%
7.21%CHF 420.00CHF 332.00CHF 159.007
Apr ’25CHF 374.00
CHF 397.14
+6.19%
7.08%CHF 420.00CHF 332.00CHF 163.707
Mar ’25CHF 349.20
CHF 390.86
+11.93%
10.52%CHF 450.00CHF 311.00CHF 195.107
Feb ’25CHF 329.60
CHF 392.29
+19.02%
10.65%CHF 450.00CHF 311.00CHF 236.007
Jan ’25CHF 342.80
CHF 412.50
+20.33%
14.77%CHF 480.00CHF 300.00CHF 201.406
Dec ’24CHF 311.60
CHF 435.00
+39.60%
8.66%CHF 480.00CHF 372.00CHF 210.005
Nov ’24CHF 266.40
CHF 447.40
+67.94%
4.85%CHF 480.00CHF 417.00CHF 220.805
CHF 202.33
Fair Value
31.6% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/28 23:23
End of Day Share Price 2025/11/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tecan Group AG is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Markus MayerBaader Helvea Equity Research
Leonildo DelgadoBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research